Company Overview

Yubo International Biotech Limited is a publicly traded biotechnology and health-related company listed on the U.S. over-the-counter market under the ticker YBGJ. Based on available public disclosures, the company has positioned itself within the biotechnology, healthcare, and wellness industries, with stated interests in biotechnology-based health products and related services. Public filings indicate that the company has historically described its business as focusing on health-related technologies and products, although specific commercial-scale operations and product penetration are limited based on available disclosures.

The company’s public history suggests it has undergone multiple strategic and operational transitions, a pattern common among micro-cap OTC-listed entities. Its evolution reflects efforts to identify viable business lines within biotechnology and health services, though consistent revenue generation and long-term operating scale are not clearly established in recent filings. Data inconclusive based on available public sources regarding sustained competitive advantages or defensible proprietary technologies.

Business Operations

According to SEC filings, Yubo International Biotech Limited reports a single consolidated operating structure rather than clearly delineated operating segments. The company has indicated involvement in health-related product development, consulting, or distribution activities, but disclosures do not consistently identify material revenue-generating products or services. Financial statements show limited operating activity, and revenue, when reported, has been modest and irregular.

The company’s operations appear primarily administrative and developmental in nature, with no clearly disclosed large-scale manufacturing assets, proprietary platforms, or clinically validated biotechnology products. There is no verified evidence of major operating subsidiaries, joint ventures, or long-term commercial partnerships. Data inconclusive based on available public sources regarding operational scalability or recurring revenue streams.

Strategic Position & Investments

Public disclosures indicate that Yubo International Biotech Limited’s strategic direction has focused on exploring potential opportunities within the biotechnology and healthcare sectors, including evaluating acquisitions, licensing arrangements, or new business models. However, filings do not confirm the completion of significant acquisitions, capital investments, or technology purchases that materially changed the company’s financial or strategic profile.

The company has periodically stated intentions to pursue growth through strategic transactions or expansion into emerging health-related markets. No verified evidence exists of controlling stakes in notable subsidiaries, ownership of patented technologies, or investments in advanced biotechnology platforms. Data inconclusive based on available public sources regarding execution of stated strategic initiatives.

Geographic Footprint

Yubo International Biotech Limited is incorporated in the United States for reporting purposes and is subject to U.S. securities regulations through its OTC listing. Operational activities disclosed in public filings suggest a primary focus on China and the Asia-Pacific region, consistent with the company’s name and stated business interests, though physical offices, staffing levels, and active facilities are not clearly documented.

The company does not report a diversified global operational footprint, and there is no verified disclosure of substantial operations in North America, Europe, or other major international markets beyond exploratory or administrative activities. Data inconclusive based on available public sources regarding the scale and continuity of international operations.

Leadership & Governance

Yubo International Biotech Limited is governed by a board of directors and executive management team as required under U.S. public company regulations. However, public disclosures provide limited and occasionally inconsistent information regarding executive tenure, role continuity, and long-term leadership structure. Governance practices follow baseline OTC reporting standards but do not indicate enhanced governance frameworks or independent committee structures comparable to larger public biotechnology companies.

Key executives disclosed in recent public filings include:

• Yong An – Chief Executive Officer
• Yong An – President
• Yong An – Director

Available public records suggest a concentration of executive authority, which may limit governance independence. Data inconclusive based on available public sources regarding broader management depth, succession planning, or articulated leadership philosophy.